To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Home / Could Cannabis Capital Markets Thrive Next Year?
Could Cannabis Capital Markets Thrive Next Year?
The marijuana capital markets have experienced a whirlwind over the past few years – and this year’s elections around the nation show little sign of affecting the capital markets no matter who comes out on top.
Historically, investors have shown high hopes for the cannabis industry, particularly in the wake of evolving state-level legalizations. Yet the capital markets have changed dramatically.
As of October, cannabis stocks such as the AdvisorShares Pure US Cannabis ETF (MSOS) are down more than 85% from their all-time highs.
Despite this sharp decline, the regulated U.S. marijuana market is larger than ever, growing from $27 billion in 2021 to an anticipated $32.1 billion by the end of 2024, according to the MJBiz Factbook.
This item originally appeared on MJBizDaily. The rest of the story is available here.
MJBizDaily
Other featured articles
Bring It On: Meet the Cannabis CMO Welcoming Scrutiny With Open Arms
By
The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture
By
Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme
By
CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited
By
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
By
Other featured Opinion articles
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
By
Is a Cannabis M&A Tidal Wave on the Way?
By
Rescheduling Will Reprice Medical IP, Not Retail Footprints
By
Organigram Acquires Sanity Group: When Big Tobacco Moves into Cannabis
By
US Cannabis Rescheduling: A Victory or a Federal Trap?
By
Share Article
Related news
Bring It On: Meet the Cannabis CMO Welcoming Scrutiny With Open Arms
By
The Right Reforms, the Wrong Narrative: Why the Medical Cannabis Debate Is Missing Half the Picture
By
Five Years, 74 Patients: Ireland Moves Forward With Review of Its Failing Medical Cannabis Programme
By
CBD Enters US Healthcare Through Medicare Pilot, But Coverage Remains Limited
By
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
By
Züri Can Extended By Two Years As Results Point To Black Market Deterrence
By
Oliver’s Law: The Campaign That Could Reshape UK Cannabis Prescribing
By
Has UK’s ‘Brexit Reset’ Derailed 5-Year CBD Approval Battle?
By
‘How Does the DEA Plan to Reschedule Without a Judge?’ – Lawmaker Demands Answers on Cannabis Rescheduling Chaos
By